Trials / Unknown
UnknownNCT05297292
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
A Multicenter, Randomized, Double-blind, Positive-controlled, Seamless Design Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (Code MW02) in the Treatment of Neovascular (Wet) Age-related Macular Degeneration (nAMD)
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 433 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of MW02 versus Lucentis in the treatment of neovascular age-related macular degeneration.The study was divided into two stages. The first stage was to explore the dose and the second stage was to explore the frequency of administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MW02 | MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection. |
| DRUG | Lucentis | a recombinant anti-VEGF humanized monoclonal antibody injection |
Timeline
- Start date
- 2021-05-07
- Primary completion
- 2023-05-15
- Completion
- 2024-06-30
- First posted
- 2022-03-28
- Last updated
- 2022-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05297292. Inclusion in this directory is not an endorsement.